Viridian Therapeutics Inc
VRDN
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,624.90 | 6.60 | -0.08% |
CAC 40 | 7,788.10 | 38.69 | -0.49% |
DAX 40 | 24,038.19 | 188.30 | -0.78% |
Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
FTSE 100 | 8,726.01 | 52.04 | -0.59% |
HKSE | 23,258.31 | 123.68 | -0.53% |
NASDAQ | 19,100.94 | 98.22 | -0.51% |
Nikkei 225 | 37,722.40 | 1.71 | -0.00% |
NZX 50 Index | 12,362.26 | 220.07 | -1.75% |
S&P 500 | 5,888.55 | 32.99 | -0.56% |
S&P/ASX 200 | 8,396.90 | 10.70 | -0.13% |
SSE Composite Index | 3,339.93 | 0.76 | -0.02% |